Correction to: Allergy Asthma Clin Immunol (2019) 15:72 https://doi.org/10.1186/s13223-019-0376-8

Following the publication of this article [1], the authors requested to amend the characterisation of ‘lanadelumab’ from ‘humanised’ to the correct ‘fully human’.

Therefore, the fourth paragraph under Recommendation #24 should be amended to read:


“Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP…”


Similarly, the first paragraph under Recommendation #27 should be amended to read:


“Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/κ-light chain)…”